These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Nov 17, 2026
these-3-dividend-stocks-have-crushed-the-market-this-year.-here’s-why-they-are-still-buys

Prosper Junior Bakiny, The Motley Fool

5 min read

Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won’t change anytime soon. But investors shouldn’t be so distracted by the AI revolution that they forget there are attractive investment opportunities elsewhere. Consider the following three healthcare dividend stocks: AbbVie (NYSE:ABBV), Gilead Sciences (NASDAQ:GILD), and Becton, Dickinson (NYSE:BDX). All three have crushed broader equities this year, and they still have plenty of upside ahead for investors willing to stay the course. Read on to find out more.

Scientist using a pipette to prepare samples at a laboratory bench

Image source: Getty Images.

Missed AI’s “Act 1”? Act 2 Could Be 16x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »

1. AbbVie

AbbVie did not perform well in the first four months of the year, but it has recovered, and its shares are now up 29% to date, while the S&P 500 has gained 10%. There are several reasons behind the drugmaker’s strong performance, perhaps none more important than its two biggest growth drivers, Skyrizi and Rinvoq. These two immunology medicines are performing better than management — and Wall Street — expected.

Considering they won’t lose patent protection anytime soon, and AbbVie will face no other major loss of patent exclusivity through the end of this decade, we can expect consistent revenue and earnings growth over the medium term. Still, Skyrizi and Rinvoq will eventually face patent cliffs, with the former perhaps starting around 2033. The good news is AbbVie is preparing for that.

AbbVie has strengthened its immunology pipeline through an acquisition and is looking to enter the fast-growing weight-loss market. Further, legacy products, especially its Botox franchise, should perform well over the long term. AbbVie’s excellent underlying business will help support its dividend program.

The company is a Dividend King, one of the corporations that have increased their payouts for at least 50 consecutive years. It would take something catastrophic for AbbVie to suspend or decrease its dividends. Until then, expect regular dividend increases alongside solid returns from the company.

2. Gilead Sciences

Gilead Sciences’ shares have gained 37% this year on the back of improving financial results and solid clinical and regulatory progress. The biotech leader still makes most of its money from its HIV franchise, with medicines like Biktarvy doing much of the heavy lifting. And even though Veklury, a coronavirus medicine, is harming top-line growth, the company has performed well.

Leave a comment